Bionova Scientific, a biologics CDMO with deep protein production, cell line development, process development and analytical expertise, today announced it initiated construction of its new state-of-the-art biologics manufacturing facility. Construction will be completed in approximately 10 months, with commissioning scheduled for Q3 2021.
The 36,000 sq. ft. facility will utilize single-use technologies for all core unit operations and is designed to accommodate two 2000L mammalian cell culture trains, capable of producing clinical and commercial bulk drug substance. Located within Bionova’s 56,000 sq. ft. headquarters, the plant is optimized for multi-product manufacturing of monoclonal antibodies and other recombinant proteins. Bionova has partnered with industry leaders DGA and Dome Construction for design and construction.
Bionova Founder and CEO Amy Kong said, “This groundbreaking is a very exciting moment for Bionova. For several years, our clients have been asking us to supplement our development capabilities so we could support their GMP production needs too. Thanks to an equity investment in 2019 by Great Point Partners and several months of detailed planning by our team, today marks an important step in Bionova’s path forward. We are grateful to our excellent clients and partners for their support and guidance as we build-out this new capability.” Great Point Partners is a healthcare-focused private equity firm based in Greenwich, Connecticut.
Bionova Co-Founder and COO Chung Chun added, “Despite the disruptions of this year, we have continued to add capabilities to support client programs. Earlier, we expanded our high-throughput automation infrastructure to support process characterization studies and process development programs. Today’s initiation of the GMP facility build-out will redefine the scope of services we can offer to the biotherapeutics industry. It will also help to fill the growing need for industry biomanufacturing capacity.”
Bionova is currently in planning discussions with clients for production slots in 2021 and beyond.
About Bionova Scientific
Founded in 2014, Bionova offers world-class biologics CDMO services built on a foundation of strong process development and analytical science with decades of experience in late stage and commercial launch projects. We firmly believe that a robust, well-understood process and well-characterized molecule are critical cornerstones of your molecule’s success. Our upstream PD group, with more than 50 benchtop bioreactors, offers a breadth and depth of capability typically found at only the largest service companies. Bionova takes an expansive view at solving client process problems. In 2019, Bionova acquired a new 57,000 sq. ft. facility in Fremont, California where we are currently expanding our development lab capabilities with new equipment and additional staff, and where we will launch our new cGMP biologics manufacturing operation in 2021.